Viking Therapeutics VKTX
Nasdaq · Pharmaceutical Preparations$25.84−1.26%Nov 19 close · Databento
Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
2 stories have a settled next close so far (2 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoRevenue$0
ROIC-83.1%
EPS, diluted$-3.19 −215.8%
Modern Valuation (EOD)
Market Cap—
Enterprise Value—
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales—
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book—
Owner & Cash Yields
True FCF Yield—
FCF Yield—
Owner Earn. Yield—
Earnings Yield—
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh—
EPS (diluted)$-3.19
Compounder & Returns
Rule of 40—
ROIC-83.1%
Cash ROIC (CROIC)—
GP / Assets—
ROE—
ROA—
Gross Margin—
Oper. Margin—
Net Margin—
FCF Margin—
True FCF Margin—
Quality & Dilution
Cash Conversion—
Accrual Ratio−11.3%
SBC % of FCF—
SBC % of Rev—
Reinvest. Rate—
Sales Growth Y/Y—
Sales 3Y CAGR—
EPS Growth Y/Y−215.8%
FCF Growth Y/Y—
FCF 3Y CAGR—
Share Change Y/Y+3.3%
Balance Sheet & Scale
Revenue (FY)$0
Gross Profit (FY)—
Oper. Income (FY)$-393.3M
GAAP Net Income—
True FCF (ex-SBC)—
Cash & Equiv$165.8M
Total Debt—
Net Cash (Debt)$165.8M
Net Cash % MCap—
Debt / FCF (yrs)—
Current Ratio9.33127.52M sh
Price & Technicals (EOD)
Perf Week−6.31%
Perf Month−2.05%
Perf Quarter−23.75%
Perf Half Y−15.78%
Perf YTD−18.64%
SMA 20 Dist−3.42%$26.76
SMA 50 Dist−10.19%$28.77
SMA 100 Dist−19.05%$31.92
Window High−38.67%$42.13
Window Low+6.73%$24.21
RSI (14) · Vol44.074%v
Revenue by fiscal year
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | — | — | |
| Research & Development (R&D) | $45.0M | $54.2M | $63.8M | $101.6M | $345.0M | +239.4% | +66.4% | |
| Total Operating Expenses | $55.7M | $70.4M | $100.8M | $150.9M | $393.3M | +160.6% | +63.0% | |
| Operating Income (EBIT) | $-55.7M | $-70.4M | $-100.8M | $-150.9M | $-393.3M | −160.6% | — | |
| Income Tax Expense | $2,000 | $1,000 | $1,000 | $1,000 | $1,000 | +0.0% | −15.9% | |
| GAAP Net Income | $-55.0M | $-68.9M | $-85.9M | $-110.0M | $-359.6M | −227.1% | — | |
| Diluted EPS | $-0.71 | $-0.90 | $-0.91 | $-1.01 | $-3.19 | −215.8% | — | |
| Diluted Shares | 77.2M | 76.8M | 94.3M | 109.0M | 112.7M | +3.3% | +9.9% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $26.4M | $36.6M | $55.5M | $26.7M | $165.8M | +521.6% | +58.4% | |
| Total Current Assets | $210.5M | $167.0M | $367.2M | $907.2M | $715.6M | −21.1% | +35.8% | |
| Total Assets | $210.7M | $168.5M | $368.5M | $908.3M | $715.7M | −21.2% | +35.8% | |
| Total Current Liabilities | $8.8M | $21.9M | $19.1M | $27.4M | $76.7M | +179.7% | +71.9% | |
| Total Liabilities | $8.8M | $23.2M | $20.1M | $28.0M | $76.7M | +173.4% | +71.9% | |
| Stockholders' Equity | $201.9M | $145.3M | $348.4M | $880.3M | $639.1M | −27.4% | +33.4% | |
| Net Cash / (Net Debt) | $26.4M | $36.6M | $55.5M | $26.7M | $165.8M | +521.6% | +58.4% | |
| Invested Capital | $175.5M | $108.7M | $292.9M | $853.6M | $473.3M | −44.6% | +28.1% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $-47.6M | $-48.4M | $-73.4M | $-87.8M | $-278.7M | −217.4% | — | |
| Stock-Based Compensation (SBC) | $6.1M | $8.7M | $16.8M | $29.7M | $40.8M | +37.4% | +60.8% | |
| Share Repurchases (Buybacks) | — | $6.8M | — | — | $6.8M | — | +0.0% | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
On the Wire
what VKTX did at the next close after each storyOct 14
Viking Therapeutics launches phase 3 trials for oral obesity drug
−4.43%Investing.com · 7:12 AM ET
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.